Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Prednisolone Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

NCT01639339
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
17
States / cities
La Palma, California • San Leandro, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 28, 2026, 10:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Medrol Dosepak for Outpatient Total Knee Arthroplasty

NCT05097976
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Methylprednisolone, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Oak Brook, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

STeroids to REduce Systemic Inflammation After Infant Heart Surgery

NCT03229538
View directory record Official record
Conditions
Congenital Heart Disease in Children, Inflammatory Response
Interventions
Methylprednisolone, Isotonic saline
Drug
Lead sponsor
Kevin Hill
Other
Eligibility
Up to 12 Months
Enrollment
1,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Corticosteroids for Children With Febrile Urinary Tract Infections

NCT01391793
View directory record Official record
Conditions
Acute Urinary Tract Infection, Urinary Tract Infection
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Months to 6 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

NCT00676832
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, COLAL-PRED
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced Sep 28, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

A Study to Prevent Infantile Spasms Relapse

NCT06819670
View directory record Official record
Conditions
Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome
Interventions
Prednisolone, Famotidine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Months to 18 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 28, 2026, 10:15 AM EDT
Withdrawn Not applicable Interventional

Arnica Montana and Bromelain in Rhinoplasty

NCT03586232
View directory record Official record
Conditions
Wound Healing
Interventions
Arnica Montana, Bromelain, Placebo
Dietary Supplement · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis

NCT00551707
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CRx-102 (2.7/180), prednisolone, dipyridamole, placebo, CRx-102 (2.7/360)
Drug
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 28, 2026, 10:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853
View directory record Official record
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
Capivasertib, Placebo, Abiraterone Acetate
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 28, 2026, 10:15 AM EDT
Withdrawn Phase 2 Interventional

Alternative Treatment Paradigm for Natalizumab Trial

NCT01710228
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
methylprednisolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

NCT02872597
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

NCT00806208
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
MEDI-507, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Timeline
1999 – 2000
U.S. locations
3
States / cities
St Louis, Missouri • Omaha, Nebraska • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Sep 28, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

NCT00443430
View directory record Official record
Conditions
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions
methotrexate, methotrexate - etanercept - prednisolone arm
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 28, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 28, 2026, 10:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
14
States / cities
Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 28, 2026, 10:15 AM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

NCT01086540
View directory record Official record
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
Biological · Other · Diagnostic Test + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 28, 2026, 10:15 AM EDT
Recruiting Phase 3 Interventional

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

NCT07623668
View directory record Official record
Conditions
Optic Neuritis
Interventions
Privosegtor, Methylprednisolone, Placebo
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 50 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Livonia, Michigan • Charleston, South Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 28, 2026, 10:15 AM EDT
Recruiting Phase 3 Interventional

Opioid-Sparing Joint Replacement

NCT07348627
View directory record Official record
Conditions
Pain Management, Opioid Consumption
Interventions
Placebo, Oxycodone 5 mg, Multimodal Non-Opioid Analgesia
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

NCT01369745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Prednisolone, dipyridamole, Prednisone, Z102, placebo
Drug · Other
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 28, 2026, 10:15 AM EDT
Terminated Phase 4 Interventional Results available

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

NCT04738318
View directory record Official record
Conditions
Elbow Fracture
Interventions
Glucocorticoids, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 28, 2026, 10:15 AM EDT